Red Spider Lily for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Red Spider Lily for Health & Longevity

Created on 09/04/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

The red spider lily is a farmed source of galantamine, a prescription memory medicine. Everything with solid human evidence concerns that purified compound. The whole plant has never been tested in people, its content varies several-fold, and eating any part of it has caused severe poisoning. For someone without dementia, the documented harms are better established than the benefits. (Full Review)

Protocol

Standard escalation schedule
8 → 16 → 24 mg daily
8 mg daily for four weeks, 16 mg for four weeks, 24 mg thereafter if tolerated. Doses above 24 mg add side effects without added benefit.
Low-dose anti-inflammatory protocol
8 → 16 mg daily
8 mg daily for four weeks, then 16 mg daily for eight weeks, targeting inflammation rather than cognition.
Pre-dawn dream protocol
4–8 mg
After roughly 4.5 hours of sleep, 30 minutes awake, then return to sleep. Used intermittently, not nightly.
Time to effect
Cognitive and functional change
3–6 months
Measured as slowed decline in diagnosed Alzheimer's dementia.
Metabolic marker shifts
4–12 weeks
Inflammatory signalling and insulin resistance in metabolic syndrome.
Gastrointestinal side effects
Within days
Cluster during dose escalation.

Benefits

Contraindications
  • Sick sinus syndrome, or second- or third-degree atrioventricular block, without a functioning pacemaker
  • Severe liver impairment (Child-Pugh Class C, 10–15 points)
  • Severe kidney impairment (creatinine clearance below 9 mL/min)
  • Active peptic ulcer disease or gastrointestinal bleeding within 90 days
  • Uncontrolled asthma, or severe chronic obstructive pulmonary disease (forced expiratory volume in one second below 50% of predicted)
  • Urinary outflow obstruction, or bladder or bowel surgery within 30 days
  • Seizure disorder, or a seizure within the past 12 months
  • Pregnancy or breastfeeding
  • The raw bulb, leaf, stem or flower in any form
  • Depolarizing neuromuscular blockers (succinylcholine) during anaesthesia without disclosure
Key Interactions
  • Beta-blockers and other rate-slowing agents (metoprolol, atenolol, diltiazem, verapamil, digoxin)
  • Anticholinergic prescription drugs (oxybutynin, tolterodine, benztropine, amitriptyline)
  • CYP2D6 and CYP3A4 inhibitors (paroxetine, fluoxetine, quinidine; ketoconazole, ritonavir, erythromycin, grapefruit juice)
  • Over-the-counter antihistamine sleep aids and motion-sickness agents (diphenhydramine, doxylamine, dimenhydrinate)
  • Over-the-counter non-steroidal anti-inflammatory drugs (ibuprofen, naproxen, aspirin)
  • Cholinergic supplements (huperzine A, alpha-glycerylphosphorylcholine, citicoline, Bacopa monnieri, nicotine)
  • Supplements with additive heart-rate-slowing or blood-pressure-lowering effects (magnesium at high dose, hawthorn, taurine, high-dose omega-3)
  • Other interventions (vagus nerve stimulation, deep slow breathing protocols, cold water immersion)

Risk & Side Effects

  • High: Gastrointestinal adverse effects; appetite loss and unintended weight loss; insomnia and depressed mood; excess mortality signal in people without dementia
  • Medium: Bradycardia, syncope and fall-related injury
    •
  • Low: Acute cholinergic poisoning from eating the raw bulb; irritant contact dermatitis from handling bulbs and sap; serious skin reactions to the purified alkaloid
  • Speculative: Cytotoxicity of narciclasine and related bulb alkaloids; unknown long-term effects of cholinesterase inhibition in cognitively healthy adults

Monitoring

Marker Target Why
Resting heart rate 55–75 beats per minute Detects cholinergic slowing before it causes fainting
Electrocardiogram, PR interval 120–200 milliseconds Identifies conduction delay that turns slowing into heart block
Body weight Within 2% of personal baseline Unintended loss is the most common persistent harm
Fasting insulin 2–5 µIU/mL Primary target of the metabolic protocol
HOMA-IR Below 1.5 Summarises insulin resistance in one number
High-sensitivity C-reactive protein Below 0.5 mg/L Tracks the inflammatory signal the compound is claimed to lower
Glycated haemoglobin 4.8–5.4% Confirms marker changes translate into glucose control
Alanine and aspartate aminotransferase Below 25 U/L for men, below 20 U/L for women Liver clearance determines exposure and dose ceiling
Estimated glomerular filtration rate Above 60 mL/min/1.73 m² Kidney clearance sets the safety floor
Serum butyrylcholinesterase No established target on treatment Falls sharply in cholinergic crisis, confirming overdose

Cadence: Baseline before starting; heart rate and weight at two weeks and at the end of each dose step; repeat electrocardiogram four weeks after the maintenance dose is reached; metabolic panel again at twelve weeks; thereafter every six to twelve months while the dose is stable. Weekly fasted weighing throughout.

Qualitative Assessment

  • Sleep quality and number of night-time awakenings, recorded each morning
  • Dream vividness and recall, which rise before any other subjective change
  • Appetite and meal completion, the earliest warning of weight loss
  • Energy and exercise tolerance, particularly whether usual paces feel harder
  • Cognitive clarity and word-finding, judged over weeks rather than days
  • Mood, given the measured excess of depressed mood on treatment
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.